Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

2003 ◽  
Vol 21 (4) ◽  
pp. 169-180 ◽  
Author(s):  
Timothy J. Littlewood ◽  
Johan Nortier ◽  
Bernardo Rapoport ◽  
Marek Pawlicki ◽  
Gilbert De Wasch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hematologic Malignancies ◽  
Epoetin Alfa ◽  
Platinum Chemotherapy

scholarly journals Correction to: An Evaluation of Adjuvant Psychological Therapy (APT) Effectiveness on the Quality of Life of Patients with Hematologic Malignancies

2018 ◽  
Vol 38 (6) ◽  
pp. 1736-1736
Author(s):  
Masoome Barani ◽  
Maryam Bakhtiari ◽  
Vahid Sadeghi Firoozabadi ◽  
Mahshid Mehdizadeh ◽  
Akram Sadeghi
Keyword(s):  
Quality Of Life ◽  
Hematologic Malignancies ◽  
Psychological Therapy

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly

2007 ◽  
Vol 15 (9) ◽  
pp. 1057-1066 ◽  
Author(s):  
Giacomo Cartenì ◽  
◽  
Laura Giannetta ◽  
Giovanni Ucci ◽  
Giorgio De Signoribus ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hemoglobin Level ◽  
Epoetin Alfa

An Evaluation of Adjuvant Psychological Therapy (APT) Effectiveness on the Quality of Life of Patients with Hematologic Malignancies

2017 ◽  
Vol 38 (6) ◽  
pp. 1728-1735
Author(s):  
Masoome Barani ◽  
Maryam Bakhtiari ◽  
Vahid Sadeghi Firoozabadi ◽  
Mahshid Mehdizadeh ◽  
Akram Sadeghi
Keyword(s):  
Quality Of Life ◽  
Hematologic Malignancies ◽  
Psychological Therapy

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

1997 ◽  
Vol 15 (3) ◽  
pp. 1218-1234 ◽  
Author(s):  
J Glaspy ◽  
R Bukowski ◽  
D Steinberg ◽  
C Taylor ◽  
S Tchekmedyian ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Functional Status ◽  
Cancer Patients ◽  
Hemoglobin Level ◽  
Activity Level ◽  
Epoetin Alfa ◽  
Open Label ◽  
Transfusion Requirements ◽  
The Impact

PURPOSE To study the impact of Procrit (epoetin alfa; Amgen Inc, Thousand Oaks, CA) on quality of life, transfusion requirements, and hemoglobin in anemic cancer patients receiving chemotherapy. PATIENTS AND METHODS More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic chemotherapy in an open-label study. Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be doubled if the therapuetic response was judged inadequate. Total treatment was up to 4 months. RESULTS Of the 2,342 patients enrolled, data were available for 2,030 patients. Of the 2,030, 1,047 patients completed all 4 months of epoetin alfa therapy. Epoetin alfa was associated with significant increases in mean self-rated scores for energy level, activity level, and overall quality of life; these improvements correlated with the magnitude of the hemoglobin increase and were independent of tumor response. In addition, epoetin alfa was associated with a significant increase in mean hemoglobin and with a significant decrease in the proportion of patients requiring transfusions (baseline to final value, P < .001). Epoetin alfa was well tolerated. CONCLUSION Epoetin alfa is effective in improving the functional status and quality of life in anemic cancer patients receiving chemotherapy, as well as increasing hemoglobin level and decreasing transfusion requirements. Improvement in functional status can be attributed to an increase in hemoglobin level, demonstrating that quality of life in this group of patients can be improved by aggressively treating anemia. Further studies will be required to define the optimal doses and schedules for epoetin alfa.

Sign in / Sign up

Export Citation Format

Share Document